Abemaciclib (Verzenio)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

Mechanism of action

From NCI Drug Dictionary: An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1.

Diseases for which it is used

History of changes in FDA indication

Also known as

  • Code name: LY2835219
  • Brand name: Verzenio